Get the Stockscreener App
305.35
1.25%
-3.875
After Hours:
305.35
0.005
+0.00%
United Therapeutics Corp stock is traded at $305.35, with a volume of 583.47K.
It is down -1.25% in the last 24 hours and up +0.28% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$309.22
Open:
$308.02
24h Volume:
583.47K
Relative Volume:
0.94
Market Cap:
$13.77B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
12.18
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
-0.37%
1M Performance:
+0.28%
6M Performance:
-5.65%
1Y Performance:
-12.57%
1-Day Range:
$305.03
$312.44
1-Week Range:
$303.59
$315.73
52-Week Range:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
305.35 | 13.98B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
155.37 | 68.60B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.86 | 46.99B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.71 | 43.17B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.05 | 20.82B | 16.70B | -157.13M | 1.19B | -0.155 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Published on: 2025-08-27 13:41:12 - Newser
Using flow based indicators on United Therapeutics CorporationWeekly Loss Report & Weekly High Return Forecasts - Newser
How hedge fund analytics apply to United Therapeutics Corporation stockMarket Activity Report & Daily Profit Focused Screening - Newser
MannKind rises as United Therapeutics expands deal (MNKD) - Seeking Alpha
Leading vs lagging indicators on United Therapeutics Corporation performanceDollar Strength & Capital Efficiency Focused Ideas - Newser
MannKind Amends License Agreement with United Therapeutics - TipRanks
United Therapeutics expands partnership with MannKind for new therapy - Investing.com
MannKind expands collaboration with United Therapeutics, receives $5 million upfront - Investing.com
MannKind Corporation Collaborates with United Therapeutics to Develop Second Dry Powder Inhalation Therapy - Quiver Quantitative
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - GlobeNewswire
How to monitor United Therapeutics Corporation with trend dashboards2025 Fundamental Recap & Consistent Profit Alerts - Newser
United Therapeutics Corporation stock trend forecastTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser
Momentum divergence signals in United Therapeutics Corporation chartQuarterly Earnings Report & High Accuracy Trade Alerts - Newser
Published on: 2025-08-26 12:14:12 - Newser
What’s next for United Therapeutics Corporation stock priceBear Alert & Low Drawdown Momentum Trade Ideas - Newser
Published on: 2025-08-26 11:15:14 - Newser
How to build a dashboard for United Therapeutics Corporation stockInsider Buying & Expert Verified Stock Movement Alerts - Newser
Historical volatility pattern of United Therapeutics Corporation visualizedWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
Detecting price anomalies in United Therapeutics Corporation with AIWeekly Loss Report & Free Real-Time Market Sentiment Alerts - Newser
Published on: 2025-08-23 04:09:17 - Newser
Can United Therapeutics Corporation hit a new high this monthJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
United Therapeutics stock holds Buy rating at UBS on Tyvaso prospects - Investing.com Nigeria
Order flow analysis tools used on United Therapeutics Corporation2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser
Key resistance and support levels for United Therapeutics CorporationEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - MSN
United Therapeutics stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
United Therapeutics stock price target raised to $415 from $385 at UBS - Investing.com
United Therapeutics stock price target raised to $415 from $385 at UBS By Investing.com - Investing.com South Africa
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer - The Globe and Mail
Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - The Globe and Mail
Should You Be Adding United Therapeutics (NASDAQ:UTHR) To Your Watchlist Today? - 富途牛牛
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey
United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest
United Therapeutics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):